What type of study is this?

This is a Human Clinical Trial study (also classified as: Pre-Registered Trial, RCT).

December 8, 2025Blood

Multivariable-adjusted validation of IWG23-defined peripheral blood complete remission (PB-CR) and IWG23 response criteria in 2,042 patients with MDS, CMML or AML treated with diverse first-line therapies: Insights from the AML-001 trial (NCT01074047) and the ‘austrian myeloid registry’ (NCT04438889) of the AGMT study group

View Full Paper

Ask AI

Bookmark

Authors

LPLisa PleyerParacelsus Medical University XZXu ZhangShanxi Medical University HAHubert Angermann

Discussion

Member takes

Implication

Multivariable analysis shows survival across treatment approaches in myeloid malignancies, indicating efficacy of IWG23-defined PB-CR and response criteria.

Key Points

Survival analysis indicates the efficacy of IWG23-defined PB-CR in myeloid malignancies.
Patients receiving azacitidine or venetoclax demonstrated significant overall survival rates.
Multivariable Cox modeling supported adjustments across treatment groups and response types.
Non-invasive PB-CR could standardize response assessment in diversely treated patients with MDS, CMML, and AML.

Cite This Study

Pleyer et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d840 https://doi.org/10.1182/blood-2025-3859

View Full Paper

Ask AI

Bookmark

Implication

Multivariable analysis shows survival across treatment approaches in myeloid malignancies, indicating efficacy of IWG23-defined PB-CR and response criteria.

Discussion

Member takes

Implication

Key Points

Cite This Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider